These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22992875)

  • 21. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
    Çiriş IM; Bozkurt KK; Başpinar S; Kapucuoğlu FN
    Pathol Res Pract; 2011 Mar; 207(3):182-7. PubMed ID: 21371829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
    Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
    Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A putative role for psoriasin in breast tumor progression.
    Krop I; März A; Carlsson H; Li X; Bloushtain-Qimron N; Hu M; Gelman R; Sabel MS; Schnitt S; Ramaswamy S; Kleer CG; Enerbäck C; Polyak K
    Cancer Res; 2005 Dec; 65(24):11326-34. PubMed ID: 16357139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
    Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
    Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical study of decorin expression in polyps and carcinomas of the colon.
    Augoff K; Rabczynski J; Tabola R; Czapla L; Ratajczak K; Grabowski K
    Med Sci Monit; 2008 Oct; 14(10):CR530-5. PubMed ID: 18830193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of ALX4 expression in epithelial cells and adjacent stromal cells in breast cancer.
    Chang H; Mohabir N; Done S; Hamel PA
    J Clin Pathol; 2009 Oct; 62(10):908-14. PubMed ID: 19783719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
    Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of HER2 protein examination in ductal carcinoma in situ.
    Horimoto Y; Tokuda E; Arakawa A; Kosaka T; Saito M; Kasumi F
    J Surg Res; 2011 May; 167(2):e205-10. PubMed ID: 20018297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression.
    Logullo AF; Nonogaki S; Pasini FS; Osório CA; Soares FA; Brentani MM
    Oncol Rep; 2010 Feb; 23(2):313-20. PubMed ID: 20043090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
    Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
    Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.
    Mangé A; Lacombe J; Bascoul-Mollevi C; Jarlier M; Lamy PJ; Rouanet P; Maudelonde T; Solassol J
    Clin Cancer Res; 2012 Apr; 18(7):1992-2000. PubMed ID: 22322670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
    Shibuya R; Suzuki T; Miki Y; Yoshida K; Moriya T; Ono K; Akahira J; Ishida T; Hirakawa H; Evans DB; Sasano H
    Endocr Relat Cancer; 2008 Mar; 15(1):113-24. PubMed ID: 18310280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
    Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
    Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High nuclear grade, frequent mitotic activity, cyclin D1 and p53 overexpression are associated with stromal invasion in mammary intracystic papillary carcinoma.
    Zhang C; Zhang P; Hao J; Quddus MR; Steinhoff MM; Sung CJ
    Breast J; 2005; 11(1):2-8. PubMed ID: 15647071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extracellular Microenvironment Alterations in Ductal Carcinoma In Situ and Invasive Breast Cancer Pathologies by Multiplexed Spatial Proteomics.
    Hulahan TS; Spruill L; Wallace EN; Park Y; West RB; Marks JR; Hwang ES; Drake RR; Angel PM
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
    Hurd TC; Sait S; Kohga S; Winston J; Martinick M; Saxena R; Lankes H; Markus G; Harvey S; Gibbs JF
    Ann Surg Oncol; 2007 Nov; 14(11):3117-24. PubMed ID: 17701256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.
    Barnes N; Haywood P; Flint P; Knox WF; Bundred NJ
    Br J Cancer; 2006 Jan; 94(2):253-8. PubMed ID: 16421596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer associated fibroblasts express pro-inflammatory factors in human breast and ovarian tumors.
    Erez N; Glanz S; Raz Y; Avivi C; Barshack I
    Biochem Biophys Res Commun; 2013 Aug; 437(3):397-402. PubMed ID: 23831470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer.
    Umbricht CB; Evron E; Gabrielson E; Ferguson A; Marks J; Sukumar S
    Oncogene; 2001 Jun; 20(26):3348-53. PubMed ID: 11423985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.